RxDoctor Payments Data

Norman Risinger, MD

Cardiovascular Disease · Austin, TXNPI 1063406692

Payments from drug & device makers

$20,790in general payments, 2019–2025

Across 660 payments — averaging $31.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$6K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Amgen$1K
  • Novartis$956
  • Johnson & Johnson$918
  • Pfizer$741
  • plus $7K from 43 others

What the payments were for

  • Speaking & faculty fees$7,36335%
  • Travel & lodging$7744%
  • Food & beverage$12,60161%
  • Education$510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,790 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$415,097
Medicare patients
1,352
Services billed
5,679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban571$689,374
EntrestoSacubitril/Valsartan139$186,095
XareltoRivaroxaban126$172,081
Repatha SureclickEvolocumab99$134,786
MultaqDronedarone Hcl67$91,832
Praluent PenAlirocumab27$26,140
BrilintaTicagrelor20$22,238
NexlizetBempedoic Acid/Ezetimibe19$19,197
Ezetimibe852$18,015
Metoprolol Succinate883$17,075
VascepaIcosapent Ethyl22$14,499
Atorvastatin Calcium1,352$12,455
Flecainide Acetate259$9,710
Icosapent Ethyl30$8,358
Losartan Potassium713$7,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$741$689,374571 claims
NovartisEntresto$956$186,095139 claims
Johnson & JohnsonXarelto$918$172,081126 claims
Sanofi-aventis U.S. LLCMultaq$5,624$91,83267 claims
AstraZenecaBrilinta$580$22,23820 claims
Esperion Therapeutics, Inc.Nexlizet$557$19,19719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →